Suppr超能文献

他克莫司在肾移植术后挽救治疗中的临床药代动力学

Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation.

作者信息

Budde K, Fritsche L, Mai I, Bauer S, Smettan S, Waiser J, Hofmann T, Hauser I, Reinke P, Neumayer H H

机构信息

Department of Internal Medicine-Nephrology, Universitätsklinikum Charité, Humboldt University, Berlin.

出版信息

Int J Clin Pharmacol Ther. 1996 Nov;34(11):493-7.

PMID:8937932
Abstract

Tacrolimus, a potent new immunosuppressive drug, was introduced for rescue therapy in 25 renal transplant recipients with ongoing rejection (n = 24) or severe cyclosporine toxicity (n = 1). A highly significant (p < 0.001) rise in serum creatinine from 138 +/- 14 (3 months before conversion) to 295 +/- 26 mumol/l preceded conversion to tacrolimus. Tacrolimus rescue therapy started 73 +/- 9 months after transplantation, the follow-up was 8 +/- 1 months. Outcome, pharmacokinetics, and side-effects were analyzed. Patient survival was 100% on tacrolimus therapy. Graft survival was 88% after 3 months, and 70% after 8 months. Serum creatinine remained stable during the observation period (Crea after 8 months: 271 +/- 26 mumol/l). Starting with an initial dose of 9.6 +/- 0.3 mg/day (0.14 +/- 0.01 mg/kg/day) we could reduce tacrolimus dose to 6.0 +/- 0.9 mg/day (0.09 +/- 0.02 mg/kg/day; p < 0.001) after 1 month. Tacrolimus trough levels were adjusted to a therapeutic window of 5-8 ng/ml. We had to perform 3.4 +/- 0.5 dose adjustments per patient mainly within the first month after conversion (70%). A high variability in interindividual tacrolimus dose was noted. Last cyclosporine dose was a good predictor of required tacrolimus dose after 1 month (r = 0.88; p < 0.001). Overall, 82 adverse events were noted, of which 29 (35%) were associated with high trough levels (> 10 ng/ml). In contrast, 3 patients with trough levels < 4 ng/ml had ongoing rejection. Blood pressure and routine laboratory data remained unchanged. Steroid dose could be tapered from 12 +/- 2 to 5 +/- 0.3 mg/day (p < 0.02). Gingival hyperplasia and hirsutism improved after conversion. We conclude: Tacrolimus conversion for rescue therapy after renal transplantation is efficient and safe with target trough levels between 5 -8 ng/ml. Frequent drug monitoring is necessary, especially within the first month after conversion. Previous cyclosporine dose can be used as a guideline for starting dose.

摘要

他克莫司是一种强效的新型免疫抑制药物,于1990年被用于25例肾移植受者的挽救治疗,这些患者存在持续性排斥反应(n = 24)或严重的环孢素毒性(n = 1)。在转换为他克莫司治疗前,血清肌酐从138±14(转换前3个月)显著升高(p < 0.001)至295±26μmol/l。他克莫司挽救治疗在移植后73±9个月开始,随访时间为8±1个月。对结果、药代动力学和副作用进行了分析。接受他克莫司治疗的患者生存率为100%。3个月时移植物存活率为88%,8个月时为70%。在观察期内血清肌酐保持稳定(8个月后肌酐:271±26μmol/l)。初始剂量为9.6±0.3mg/天(0.14±0.01mg/kg/天),1个月后他克莫司剂量可降至6.0±0.9mg/天(0.09±0.02mg/kg/天;p < 0.001)。他克莫司谷浓度调整至5 - 8ng/ml的治疗窗。每位患者平均需要进行3.4±0.5次剂量调整,主要在转换后的第一个月内(70%)。观察到个体间他克莫司剂量存在高度变异性。末次环孢素剂量是1个月后所需他克莫司剂量的良好预测指标(r = 0.88;p < 0.001)。总体而言,共记录到82例不良事件,其中29例(35%)与高谷浓度(> 10ng/ml)相关。相比之下,3例谷浓度< 4ng/ml的患者存在持续性排斥反应。血压和常规实验室数据保持不变。类固醇剂量可从12±2mg/天逐渐减至5±0.3mg/天(p < 0.02)。转换后牙龈增生和多毛症有所改善。我们得出结论:肾移植后转换为他克莫司进行挽救治疗是有效且安全的,目标谷浓度在5 - 8ng/ml之间。需要频繁进行药物监测,尤其是在转换后的第一个月内。先前的环孢素剂量可作为起始剂量的指导。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验